Ipsen is acquiring global rights to a Sutro Biopharma antibody drug conjugate for a target that is not yet hit by any FDA-approved drugs. Merck is among the companies pursuing this target, but Sutro claims its ADC could be first and best in this class.
The post Ipsen Joins the ADC Chase, Licensing Phase 1-Ready Asset for Novel Cancer Target appeared first on MedCity News.
Leave a comment